SCHEMBL3367760

SCHEMBL3367760

[O-][n+]1ccc(-c2ccccc2)c2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.61
RCE1 Q9Y256 1/20 0.61
ACHE P22303 2/20 0.38
BACE1 P56817 1/20 0.37
MAPT P10636 3/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MPI P34949 1/20 0.36
TACR1 P25103 2/20 0.36
BCL2L1 Q07817 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MITF O75030 1/20 0.35
BRD4 O60885 2/20 0.35
GPR84 Q9NQS5 1/20 0.35
MAPK14 Q16539 1/20 0.35
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4659415 0.83 ALOX5 (0.46) RAB9ARCE1BACE1MAPTALDH1A1
SCHEMBL12277535 0.79 RAB9A (0.41) RAB9ARCE1ALDH1A1MEN1KMT2A
SCHEMBL633559 0.76 RAB9A (0.36) RAB9ARCE1MAPTKDM4EMITF
SCHEMBL30915429 0.76 BRD4 (0.51) RAB9ARCE1BRD4
SCHEMBL1193736 0.75 IDO1 (0.44) RAB9ARCE1MAPTALDH1A1HPGD
SCHEMBL12074977 0.73 RAB9A (0.83) RAB9ARCE1ACHEMAPTHPGD
SCHEMBL3194423 0.73 NR4A1 (0.46) MAPTALDH1A1HPGDKDM4EMEN1
SCHEMBL1770982 0.71 MAPT (0.39) RAB9ARCE1ACHEMAPTALDH1A1
SCHEMBL7155648 0.71 MITF (0.37) RAB9ARCE1ACHEMAPTMITF
SCHEMBL2795974 0.71 CYP2A6 (0.44) RAB9ARCE1MAPTKMT2AMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756085-B1 DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4-(3-CHLOROPHENYL)-2-METHOXY-QUINOLINE JANSSEN PHARMACEUTICA NV (BE) 2010-06-16 EP disclosed
US-7572916-B2 Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline JANSSEN PHARMACEUTICA NV (BE) 2009-08-11 US disclosed
US-20070293680-A1 For the preparation of (R)-(+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl2(1H)-quinolinone; farnesyl tranferase inhibitory activity JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-20 US disclosed
EP-1756085-A1 DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4-(3-CHLOROPHENYL)-2-METHOXY-QUINOLINE JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-28 EP disclosed
WO-2005105783-A1 DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4-(3-CHLOROPHENYL)-2-METHOXY-QUINOLINE JANSSEN PHARMACEUTICA N.V. (BE) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293680-A1 For the preparation of (R)-(+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl2(1H)-quinolinone; farnesyl tranferase inhibitory activity FNTB, CYP4F2, FNTA RAB9A 854/4885RCE1 4/4885ACHE 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.